Sign In
Buy RDHL
$1.00
-0.0100 (-0.99%)
At Close: Jun 03, 2026
RedHill Biopharma Receives Nasdaq Staff Determination Notification
04:50pm, Wednesday, 22'nd Oct 2025
On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum stockholders' equity requirements for
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
09:05am, Monday, 20'th Oct 2025
Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy NASHVILLE, Tenn. , Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX)
RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®
08:00am, Monday, 06'th Oct 2025
The deal aims to accelerate Talicia's entry into new Middle East markets Under the terms of the agreement RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment a
RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo
07:00am, Monday, 29'th Sep 2025
The New York Supreme Court has, on appeal, upheld its original summary judgment ruling in favor of RedHill The New York Supreme Court unequivocally dismissed Kukbo Co. Ltd's ("Kukbo") defense again, f
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights
07:00am, Friday, 05'th Sep 2025
Extensive strategic, financial and operational overhaul has reshaped and refocused our business; Strong progress on multiple fronts Commercial and R&D Highlights: Recruitment initiated in the Bayer-s
The New York Supreme Court has awarded RedHill approximately $1.82 million in legal costs and expenses following, and in addition to, the Court's prior summary judgment of approximately $8.25 million
RedHill Received Talicia® Licensing Payments Totaling $1.1 Million
09:00am, Monday, 18'th Aug 2025
RedHill has received its first Talicia sales milestone payment as well as royalties and other payments, totaling $1.1 million, following the first ex-U.S. commercial launch of Talicia in 2024 Talicia
RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease
09:00am, Monday, 21'st Jul 2025
The positive FDA feedback allows for: A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium subspecies paratuberculosis infected (
Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and Ramsay Hospital Research Foundation Pr
Korea's Incheon District Court attachment grant prevents asset disposal by Kukbo prior to enforcement , following the New York Supreme Court's approximately $8.25 million plus legal fees and costs sum
RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress
07:00am, Friday, 02'nd May 2025
RedHill supports an independent medical education grant that includes a new two-part H. Pylori Continuing Medical Education (CME) program, developed by Medscape aimed at advancing clinical knowledge a
RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107
07:03am, Monday, 28'th Apr 2025
Strong Use of Composition-of-Matter Coverage: Patent protects the molecular structure of RHB-107, providing market exclusivity beyond method-of-use claims COVID-19 Therapeutic Use: Includes coverage f
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
04:01pm, Thursday, 17'th Apr 2025
The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected by receipt of the Notification Le
RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption
07:00am, Wednesday, 16'th Apr 2025
GLP-1 comparable efficacy: Opaganib's positive results, newly published in the journal Diabetes, Metabolic Syndrome and Obesity, demonstrated weight loss and improved metabolic markers on par with sem
RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights
07:48am, Thursday, 10'th Apr 2025
Revenue-generating with an exciting, diversified, largely externally funded, advanced development pipeline and multiple upcoming catalysts. Recent highlights: Global licensing deal (excluding North Am
